High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Tempus AI Inc (TEM) reports strong Q2 2026 results with record revenue, FDA approval for xT CDx, and a major BioNTech partnership, driving a raised outlook for 25% annual growth.
Tempus (TEM) delivered earnings and revenue surprises of +69.23% and +0.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood, CEO of Ark Investment Management, is known for buying her favorite growth stocks during sharp pullbacks. That's exactly what she's doing with Tempus AI (TEM) after the healthcare technology stock tumbled 14% over the past week. In 2025, the flagship Ark Innovation ETF gained ...
Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.